NIH Precision Medicine Data Reveals 275M New Genetic Variants

Researchers found more than 275 million previously unreported genetic variants in data shared by nearly 250,000 National Institutes of Health's Global Research Program participants.

Innovative Meds: Global-Domestic Pharma Collaboration in India

Indian drug firms are exploring opportunities in the Kingdom of Saudi Arabia (KSA), an $8.9 billion pharmaceutical (pharma) market, as the latter is keen to procure more pharmaceutical products from India.

India Pharma Giants & Global Big Pharma Partner for NMEs in India

The pharma landscape has significantly shifted towards collaboration and partnership between global big pharma and Indian pharma firms in recent years to drive innovation and expand market reach.

Innovent Biologics Concludes Phase 3 Trial To Treat Thyroid Eye Disease

The primary endpoint in the phase 3 registrational study (RESTORE-1) of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in Chinese subjects with thyroid eye disease (TED) has been achieved, according to...

NIMHANS Mental Health Santhe 2.0: Setting New Standards

National Institute of Mental Health and Neuro Sciences (NIMHANS) ‘Mental Health Santhe 2.0 sets new standards in mental health awareness.

Union Health Minister Urges Global Collaboration for Digital Health Framework

Dr Mansukh Mandaviya, Union minister of health and family welfare, urged all member countries of the World Health Organisation (WHO) to join hands to strengthen the global digital health framework, which will empower countries

GE HealthCare & OSF HealthCare Partner for Comprehensive Care Solutions

GE HealthCare, a leading global medical technology, pharma diagnostics, and digital solutions innovator, has announced a collaboration with Illinois-headquartered OSF HealthCare for an integrated health system caring for patients

Bayer's Phase II Study: Anti-alpha2 Antibody for Deep Vein Thrombosis

Bayer announced the initiation of a Phase 2 clinical trial (SIRIUS study) for BAY3018250, the first anti-alpha2 antiplasmin (anti-a2ap) antibody in patients with deep vein thrombosis (DVT).

Pfizer's Velsipity Approved for Active Ulcerative Colitis in Europe

Pfizer Inc. received marketing approval. Velsipiti (ethrasimod) in the European Union for the treatment of patients with mild to severe ulcerative colitis (UC) did not respond adequately if there is no response to current therapies or biologics.

Global Firms Dominate 60% of Indian Vaccine Sales

Global pharmaceutical companies lead the Indian vaccine market with a value share of 60% India's vaccine market is still recovering from the impact of COVID-19, and many nations have regained strength, according to data from research firm Pharm.

© 2025 India Pharma Outlook. All Rights Reserved.